These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil. Mason RP Vasc Health Risk Manag; 2011; 7():405-16. PubMed ID: 21796255 [TBL] [Abstract][Full Text] [Related]
10. Vascular endothelin in hypertension. Schiffrin EL Vascul Pharmacol; 2005 Jun; 43(1):19-29. PubMed ID: 15955745 [TBL] [Abstract][Full Text] [Related]
11. Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension. Kowala MC; Murugesan N; Tellew J; Carlson K; Monshizadegan H; Ryan C; Gu Z; Kane B; Fadnis L; Baska RA; Beyer S; Arthur S; Dickinson K; Zhang D; Perrone M; Ferrer P; Giancarli M; Baumann J; Bird E; Panchal B; Yang Y; Trippodo N; Barrish J; Macor JE J Pharmacol Exp Ther; 2004 Apr; 309(1):275-84. PubMed ID: 14718594 [TBL] [Abstract][Full Text] [Related]
12. A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug. Chrysant SG Expert Opin Drug Saf; 2021 Jun; 20(6):635-640. PubMed ID: 33734912 [TBL] [Abstract][Full Text] [Related]
13. Smooth muscle-specific deletion of nitric oxide-sensitive guanylyl cyclase is sufficient to induce hypertension in mice. Groneberg D; König P; Wirth A; Offermanns S; Koesling D; Friebe A Circulation; 2010 Jan; 121(3):401-9. PubMed ID: 20065162 [TBL] [Abstract][Full Text] [Related]
14. A rationale for treatment of endothelial dysfunction in hypertension. Ruschitzka F; Corti R; Noll G; Lüscher TF J Hypertens Suppl; 1999 Feb; 17(1):S25-35. PubMed ID: 10340841 [TBL] [Abstract][Full Text] [Related]
15. Endothelin as a regulator of cardiovascular function in health and disease. Haynes WG; Webb DJ J Hypertens; 1998 Aug; 16(8):1081-98. PubMed ID: 9794709 [TBL] [Abstract][Full Text] [Related]
16. Soluble guanylyl cyclase is a target of angiotensin II-induced nitrosative stress in a hypertensive rat model. Crassous PA; Couloubaly S; Huang C; Zhou Z; Baskaran P; Kim DD; Papapetropoulos A; Fioramonti X; Durán WN; Beuve A Am J Physiol Heart Circ Physiol; 2012 Sep; 303(5):H597-604. PubMed ID: 22730391 [TBL] [Abstract][Full Text] [Related]
17. Effects of captopril on the renin angiotensin system, oxidative stress, and endothelin in normal and hypertensive rats. Bolterman RJ; Manriquez MC; Ortiz Ruiz MC; Juncos LA; Romero JC Hypertension; 2005 Oct; 46(4):943-7. PubMed ID: 16087785 [TBL] [Abstract][Full Text] [Related]
18. Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. Mazzuca MQ; Khalil RA Biochem Pharmacol; 2012 Jul; 84(2):147-62. PubMed ID: 22484314 [TBL] [Abstract][Full Text] [Related]
19. Hypertension: renin-angiotensin-aldosterone system alterations. Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283 [TBL] [Abstract][Full Text] [Related]